Prevalence and Clinical Significance of Potential Drug-Drug Interaction in Hematopoietic Stem Cell Transplantation
Investigators performed a cross-sectional study based on the evaluation of prescriptions to hematopoietic stem cell transplantation patients on the day of infusion. The potential drug-drug interactions were analyzed using the DRUG-REAX® system and classified according to the severity level, available scientific evidence, time of onset, and potential clinical impact. [Cancer Chemother Pharmacol] Abstract
ARIAD Announces Phase II Dose-Ranging Trial of Iclusig (Ponatinib) to Begin by Mid-2015
ARIAD Pharmaceuticals, Inc. announced that it has concluded consultations with U.S. and European health authorities regarding the design of a randomized, dose-ranging trial to evaluate three starting doses of Iclusig® in patients with refractory, chronic-phase chronic myeloid leukemia. [ARIAD Pharmaceuticals, Inc.] Press Release
Recruit Top Talent: Reach more than 50,000 potential candidates by posting
your organization’s career opportunities on the Connexon Creative Job Board at no cost.
Have we missed an important article or publication in Cord Blood News? Click here to submit!